3.5.1.108 (2R)-4-(2'-ethyl[1,1'-biphenyl]-4-yl)-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237660 3.5.1.108 (2R)-4-(2'-fluoro[1,1'-biphenyl]-4-yl)-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237661 3.5.1.108 (2R)-4-(3'-chloro[1,1'-biphenyl]-4-yl)-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237662 3.5.1.108 (2R)-4-(3-fluoro-2-oxo-4-phenylpyridin-1(2H)-yl)-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237663 3.5.1.108 (2R)-4-(4'-cyano[1,1'-biphenyl]-4-yl)-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237664 3.5.1.108 (2R)-4-(4'-fluoro[1,1'-biphenyl]-4-yl)-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237665 3.5.1.108 (2R)-4-(4-cyclohexyl-2-oxopyridin-1(2H)-yl)-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237666 3.5.1.108 (2R)-4-(4-tert-butyl-2-oxopyridin-1(2H)-yl)-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237667 3.5.1.108 (2R)-4-(5-fluoro-2-oxo-4-phenylpyridin-1(2H)-yl)-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237668 3.5.1.108 (2R)-4-([1,1'-biphenyl]-4-yl)-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 204524 3.5.1.108 (2R)-4-[3-(2,3-difluorophenyl)-1,2-oxazol-5-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237670 3.5.1.108 (2R)-4-[3-(2-fluoro-3-methoxyphenyl)-1,2-oxazol-5-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237671 3.5.1.108 (2R)-4-[3-(2-fluoro-4-methoxyphenyl)-1,2-oxazol-5-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237672 3.5.1.108 (2R)-4-[4'-(3-aminopropoxy)[1,1'-biphenyl]-4-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237673 3.5.1.108 (2R)-4-[4'-(3-carbamimidamidopropoxy)[1,1'-biphenyl]-4-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237674 3.5.1.108 (2R)-4-[4'-(aminomethyl)[1,1'-biphenyl]-4-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237675 3.5.1.108 (2R)-4-[4-(2,3-dichlorophenyl)-1H-1,2,3-triazol-1-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237676 3.5.1.108 (2R)-4-[4-(2,3-difluorophenyl)-1H-1,2,3-triazol-1-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237677 3.5.1.108 (2R)-4-[4-(2,5-difluorophenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237678 3.5.1.108 (2R)-4-[4-(2,6-difluorophenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237679 3.5.1.108 (2R)-4-[4-(2-chloro-4-methoxyphenyl)-1H-1,2,3-triazol-1-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237680 3.5.1.108 (2R)-4-[4-(2-fluoro-3-methoxyphenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237681 3.5.1.108 (2R)-4-[4-(2-fluoro-4-methoxyphenyl)-1H-1,2,3-triazol-1-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237682 3.5.1.108 (2R)-4-[4-(2-fluoro-4-methoxyphenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 204525 3.5.1.108 (2R)-4-[4-(2-fluorophenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237683 3.5.1.108 (2R)-4-[4-(2H-1,3-benzodioxol-5-yl)phenyl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237684 3.5.1.108 (2R)-4-[4-(3,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237685 3.5.1.108 (2R)-4-[4-(3,4-difluorophenyl)-1H-1,2,3-triazol-1-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237686 3.5.1.108 (2R)-4-[4-(3,5-difluorophenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237687 3.5.1.108 (2R)-4-[4-(3,5-dimethylphenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237688 3.5.1.108 (2R)-4-[4-(3-fluoro-4-methoxyphenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237689 3.5.1.108 (2R)-4-[4-(3-fluorophenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237690 3.5.1.108 (2R)-4-[4-(4-chloro-2,3-difluorophenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237691 3.5.1.108 (2R)-4-[4-(4-chloro-2-fluorophenyl)-1H-1,2,3-triazol-1-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237692 3.5.1.108 (2R)-4-[4-(4-chloro-2-fluorophenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237693 3.5.1.108 (2R)-4-[4-(4-chloro-3-fluorophenyl)-1H-1,2,3-triazol-1-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237694 3.5.1.108 (2R)-4-[4-(4-fluorophenyl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237695 3.5.1.108 (2R)-4-[4-(benzyloxy)phenyl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237696 3.5.1.108 (2R)-4-[4-(cyclohex-1-en-1-yl)-2-oxopyridin-1(2H)-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237697 3.5.1.108 (2R)-4-[4-(cyclopentyloxy)phenyl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237698 3.5.1.108 (2R)-4-[5-(2,3-dichlorophenyl)-1,2-oxazol-3-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237699 3.5.1.108 (2R)-4-[5-(2-fluoro-4-methoxyphenyl)-1,2-oxazol-3-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237700 3.5.1.108 (2R)-4-[5-(2-fluorophenyl)-1,2-oxazol-3-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237701 3.5.1.108 (2R)-4-[5-(3-fluorophenyl)-1,2-oxazol-3-yl]-N-hydroxy-2-(methanesulfonyl)-2-methylbutanamide - 237702 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-(1-phenyl-1H-1,2,3-triazol-4-yl)butanamide - 237705 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-(1-phenyl-1H-pyrazol-4-yl)butanamide - 237706 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-(2'-oxo[2,4'-bipyridin]-1'(2'H)-yl)butanamide - 237707 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-(2-oxo-4-phenylpyridin-1(2H)-yl)butanamide - 204529 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-(2-oxo-4-phenylpyrimidin-1(2H)-yl)butanamide - 237708 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-(2-oxo[4,4'-bipyridin]-1(2H)-yl)butanamide - 237709 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-(3-methyl-2-oxo-4-phenylpyridin-1(2H)-yl)butanamide - 237710 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-(3-phenyl-1,2-oxazol-5-yl)butanamide - 237711 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-(4-oxo-7-phenylquinazolin-3(4H)-yl)butanamide - 204530 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-(4-phenyl-1H-1,2,3-triazol-1-yl)butanamide - 237712 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-(4-phenyl-1H-pyrazol-1-yl)butanamide - 237713 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-(5-methyl-2-oxo-4-phenylpyridin-1(2H)-yl)butanamide - 237714 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-(5-phenyl-1,2-oxazol-3-yl)butanamide - 237715 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-(5-phenylpyridin-2-yl)butanamide - 237716 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-(6-methyl-2-oxo-4-phenylpyridin-1(2H)-yl)butanamide - 237717 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-(6-oxo-4-phenylpyrimidin-1(6H)-yl)butanamide - 237718 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-(6-phenylpyridin-3-yl)butanamide - 237719 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-[2-oxo-4-(2,3,4-trifluorophenyl)pyridin-1(2H)-yl]butanamide - 237720 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-[2-oxo-4-(2-phenylethyl)pyridin-1(2H)-yl]butanamide - 237721 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-[2-oxo-4-(phenylethynyl)pyridin-1(2H)-yl]butanamide - 237722 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-[2-oxo-4-[(E)-2-phenylethenyl]pyridin-1(2H)-yl]butanamide - 237723 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-[2-oxo-4-[4-(1,3-thiazol-2-yl)phenyl]pyridin-1(2H)-yl]butanamide - 237724 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-[2-oxo-4-[4-(2H-1,2,3-triazol-2-yl)phenyl]pyridin-1(2H)-yl]butanamide - 237725 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-[2-oxo-4-[4-(pyridin-2-yl)phenyl]pyridin-1(2H)-yl]butanamide - 237726 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-[2-oxo-4-[4-(pyridin-4-yl)phenyl]pyridin-1(2H)-yl]butanamide - 237727 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-[3'-(1H-pyrazol-1-yl)[1,1'-biphenyl]-4-yl]butanamide - 237728 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-[3'-(propan-2-yl)[1,1'-biphenyl]-4-yl]butanamide - 237729 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-[3-(4-methylphenyl)-1,2-oxazol-5-yl]butanamide - 237730 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-[4-(4-methylphenyl)-1H-1,2,3-triazol-1-yl]butanamide - 237731 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-[4-(naphthalen-2-yl)-2-oxopyridin-1(2H)-yl]butanamide - 237732 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-[4-(phenylsulfanyl)phenyl]butanamide - 237733 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-[4-(pyridin-3-yl)phenyl]butanamide - 237734 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-[4-[(pyridin-4-yl)oxy]phenyl]butanamide - 237735 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-2-methyl-4-[4-[4-(1,2-oxazol-3-yl)phenyl]-2-oxopyridin-1(2H)-yl]butanamide - 237736 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-4-(2'-methoxy[1,1'-biphenyl]-4-yl)-2-methylbutanamide - 237737 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-4-(6-methoxy-2'-oxo[3,4'-bipyridin]-1'(2'H)-yl)-2-methylbutanamide - 237738 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-4-[4-(2-methoxyphenyl)-2-oxopyridin-1(2H)-yl]-2-methylbutanamide - 237739 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-4-[4-(3-methoxyphenyl)-2-oxopyridin-1(2H)-yl]-2-methylbutanamide - 237740 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-4-[4-(4-methoxyphenyl)-2-oxopyridin-1(2H)-yl]-2-methylbutanamide - 237741 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-4-[4-[4-(2-methoxypyrimidin-5-yl)phenyl]-2-oxopyridin-1(2H)-yl]-2-methylbutanamide - 237742 3.5.1.108 (2R)-N-hydroxy-2-(methanesulfonyl)-4-[4-[4-(5-methoxypyrimidin-2-yl)phenyl]-2-oxopyridin-1(2H)-yl]-2-methylbutanamide - 237743 3.5.1.108 (2R)-N-hydroxy-2-[(naphthalene-2-sulfonyl)methyl]-3-(naphthalen-2-yl)propanamide - 204531 3.5.1.108 (2R)-N-hydroxy-3-naphthalen-2-yl-2-[(naphthalen-2-ylsulfonyl)amino]propanamide potent inhibitor, shows antibacterial activity against a wide range of Gram-negative pathogens, binding mode 151870 3.5.1.108 (2R)-N-hydroxy-4-(2-hydroxy-6-phenylpyridin-3-yl)-2-(methanesulfonyl)-2-methylbutanamide - 237744 3.5.1.108 (2R)-N-hydroxy-4-[4'-(hydroxyacetyl)[1,1'-biphenyl]-4-yl]-2-(methanesulfonyl)-2-methylbutanamide - 237745 3.5.1.108 (2R,3R,4S,5S)-N,3,4-trihydroxy-5-[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)phenyl]oxolane-2-carboxamide - 237753 3.5.1.108 (2S)-N,3-dihydroxy-2-[(1S)-2-hydroxy-1-[4-(phenylethynyl)phenyl]ethoxy]propanamide - 237765 3.5.1.108 (2S)-N,3-dihydroxy-2-[(1S)-2-hydroxy-1-[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)phenyl]ethoxy]propanamide - 237766 3.5.1.108 (2S)-N1-hydroxy-2-[4-(phenylethynyl)benzamido]butanediamide - 237769 3.5.1.108 (2S,3R)-2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-2-methyl-3-(1,2-oxazol-5-yl)propanamide - 237770 3.5.1.108 (2S,3R)-2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-2-methyl-3-(1,3-oxazol-2-yl)propanamide - 237771 3.5.1.108 (2S,3R)-2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-2-methylbutanamide - 237772 3.5.1.108 (2S,3R)-2-[5-([1,1'-biphenyl]-4-yl)-1-oxo-1,3-dihydro-2H-isoindol-2-yl]-N,3-dihydroxybutanamide - 237773 3.5.1.108 (2S,3R)-2-[5-[([1,1'-biphenyl]-3-yl)ethynyl]-1-oxo-1,3-dihydro-2H-isoindol-2-yl]-N,3-dihydroxybutanamide - 237774 3.5.1.108 (2S,3R)-2-[5-[([1,1'-biphenyl]-4-yl)ethynyl]-1-oxo-1,3-dihydro-2H-isoindol-2-yl]-N,3-dihydroxybutanamide - 237775 3.5.1.108 (2S,3R)-N,3-dihydroxy-2-(1-oxo-5-phenyl-1,3-dihydro-2H-isoindol-2-yl)butanamide - 237776 3.5.1.108 (2S,3R)-N,3-dihydroxy-2-[1-oxo-5-(phenylethynyl)-1,3-dihydro-2H-isoindol-2-yl]butanamide - 237777 3.5.1.108 (2S,3R)-N,3-dihydroxy-2-[1-oxo-5-[4-(phenylethynyl)phenyl]-1,3-dihydro-2H-isoindol-2-yl]butanamide - 237778 3.5.1.108 (2S,3R)-N,3-dihydroxy-2-[1-oxo-6-(phenylethynyl)-1,3-dihydro-2H-isoindol-2-yl]butanamide - 237779 3.5.1.108 (2S,3R)-N,3-dihydroxy-2-[3-oxo-6-(phenylethynyl)-1,3-dihydro-2H-indazol-2-yl]butanamide - 237780 3.5.1.108 (2S,3R,4S,5R)-5-(1-benzyl-1H-1,2,3-triazol-4-yl)-N,3,4-trihydroxyoxolane-2-carboxamide - 204546 3.5.1.108 (2S,3R,4S,5R)-5-(1-hexyl-1H-1,2,3-triazol-4-yl)-N,3,4-trihydroxyoxolane-2-carboxamide - 204547 3.5.1.108 (2S,3R,4S,5R)-5-[1-[(4-fluorophenyl)methyl]-1H-1,2,3-triazol-4-yl]-N,3,4-trihydroxyoxolane-2-carboxamide - 204548 3.5.1.108 (2S,3R,4S,5R)-N,3,4-trihydroxy-5-(1-phenyl-1H-1,2,3-triazol-4-yl)oxolane-2-carboxamide - 204549 3.5.1.108 (2S,3R,4S,5R)-N,3,4-trihydroxy-5-(1-[[4-(trifluoromethyl)phenyl]methyl]-1H-1,2,3-triazol-4-yl)oxolane-2-carboxamide - 204550 3.5.1.108 (2S,3R,4S,5R)-N,3,4-trihydroxy-5-(2-(4-[2-(4-methoxyphenyl)ethynyl]phenyl)ethynyl)tetrahydrofuran-2-carboxamide - 206436 3.5.1.108 (2S,3R,4S,5R)-N,3,4-trihydroxy-5-(octa-1,3-diyn-1-yl)tetrahydrofuran-2-carboxamide - 204552 3.5.1.108 (2S,3R,4S,5R)-N,3,4-trihydroxy-5-(phenylbuta-1,3-diyn-1-yl)tetrahydrofuran-2-carboxamide - 204553 3.5.1.108 (2S,3R,4S,5R)-N,3,4-trihydroxy-5-([4-(phenylethynyl)phenyl]ethynyl)tetrahydrofuran-2-carboxamide - 206432 3.5.1.108 (2S,3R,4S,5R)-N,3,4-trihydroxy-5-[1-(2-phenylethyl)-1H-1,2,3-triazol-4-yl]oxolane-2-carboxamide - 204554 3.5.1.108 (2S,3R,4S,5R)-N,3,4-trihydroxy-5-[1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl]oxolane-2-carboxamide - 204555 3.5.1.108 (2S,3R,4S,5R)-N,3,4-trihydroxy-5-[2-(4-(2-[4-(trifluoromethyl)phenyl]ethynyl)phenyl)ethynyl]tetrahydrofuran-2-carboxamide - 206434 3.5.1.108 (2S,3R,4S,5S)-5-(1-benzyl-1H-1,2,3-triazol-4-yl)-N,3,4-trihydroxytetrahydrofuran-2-carboxamide - 204558 3.5.1.108 (2S,3R,4S,5S)-5-[1-(4-fluorobenzyl)-1H-1,2,3-triazol-4-yl]-N,3,4-trihydroxytetrahydrofuran-2-carboxamide - 204559 3.5.1.108 (2S,3R,4S,5S)-N,3,4-trihydroxy-5-((4-[(4-methoxyphenyl)ethynyl]phenyl)ethynyl)tetrahydrofuran-2-carboxamide - 206437 3.5.1.108 (2S,3R,4S,5S)-N,3,4-trihydroxy-5-(1-phenethyl-1H-1,2,3-triazol-4-yl)tetrahydrofuran-2-carboxamide - 204560 3.5.1.108 (2S,3R,4S,5S)-N,3,4-trihydroxy-5-(1-phenyl-1H-1,2,3-triazol-4-yl)tetrahydrofuran-2-carboxamide - 204561 3.5.1.108 (2S,3R,4S,5S)-N,3,4-trihydroxy-5-(1-[4-(trifluoromethyl)benzyl]-1H-1,2,3-triazol-4-yl)tetrahydrofuran-2-carboxamide - 206438 3.5.1.108 (2S,3R,4S,5S)-N,3,4-trihydroxy-5-(phenylbuta-1,3-diyn-1-yl)tetrahydrofuran-2-carboxamide - 204562 3.5.1.108 (2S,3R,4S,5S)-N,3,4-trihydroxy-5-([4-(phenylethynyl)phenyl]ethynyl)tetrahydrofuran-2-carboxamide - 206433 3.5.1.108 (2S,3R,4S,5S)-N,3,4-trihydroxy-5-[(4-([4-(trifluoromethyl)phenyl]ethynyl)phenyl)ethynyl]tetrahydrofuran-2-carboxamide - 206435 3.5.1.108 (2S,3R,4S,5S)-N,3,4-trihydroxy-5-[1-(3-phenylpropyl)-1H-1,2,3-triazol-4-yl]tetrahydrofuran-2-carboxamide - 204565 3.5.1.108 (2S,3R,4S,5S)-N,3,4-trihydroxy-5-[4-(4-phenylbuta-1,3-diyn-1-yl)phenyl]oxolane-2-carboxamide - 204566 3.5.1.108 (2S,3R,4S,5S)-N,3,4-trihydroxy-5-[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)phenyl]oxolane-2-carboxamide - 204567 3.5.1.108 (2S,3S)-2-[([1,1'-biphenyl]-4-yl)methoxy]-5-ethoxy-N,3-dihydroxy-2-methylpentanamide - 237781 3.5.1.108 (2S,3S)-2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-2,4-dimethylpentanamide - 237782 3.5.1.108 (2S,3S)-2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-2-methyl-3-(1,2-oxazol-3-yl)propanamide - 237783 3.5.1.108 (2S,3S)-2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-2-methyl-3-(1-methyl-1H-1,2,3-triazol-5-yl)propanamide - 237784 3.5.1.108 (2S,3S)-2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-2-methyl-3-(1-methyl-1H-imidazol-2-yl)propanamide - 237785 3.5.1.108 (2S,3S)-2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-2-methyl-3-(1H-pyrazol-5-yl)propanamide - 237786 3.5.1.108 (2S,3S)-2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-2-methyl-3-(5-methyl-1,2-oxazol-3-yl)propanamide - 237787 3.5.1.108 (2S,3S)-2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-2-methyl-3-(pyridin-2-yl)propanamide - 237788 3.5.1.108 (2S,3S)-2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-2-methyl-3-(pyridin-3-yl)propanamide - 237789 3.5.1.108 (2S,3S)-2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-2-methyl-3-phenylpropanamide - 237790 3.5.1.108 (2S,3S)-2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-2-methylbutanamide - 237791 3.5.1.108 (2S,3S)-2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-2-methylheptanamide - 237792 3.5.1.108 (2S,3S)-2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-2-methylpentanamide - 237793 3.5.1.108 (2S,3S)-2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-3-(1H-imidazol-5-yl)-2-methylpropanamide - 237794 3.5.1.108 (2S,3S)-2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-3-[5-(hydroxymethyl)-1,2-oxazol-3-yl]-2-methylpropanamide - 237795 3.5.1.108 (2S,4S,5S)-N,4-dihydroxy-5-[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)phenyl]oxolane-2-carboxamide - 237796 3.5.1.108 (3-(4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl)methanethiol - 74130 3.5.1.108 (3R,5R)-3-hydroxy-5-(2-(hydroxyamino)-2-oxoethyl)-2-(hydroxymethyl)tetrahydro-2H-pyran-4-yl tetradecanoate substrate-analog LpxC inhibitor, possesses little or no antibacterial activity, because it probably cannot penetrate the Gram-negative cell envelope 26328 3.5.1.108 (3S,4R)-N,3,4-trihydroxy-1-[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)benzoyl]-L-prolinamide - 237835 3.5.1.108 (4R)-2-(1-benzothiophen-2-yl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 10% inhibition 237838 3.5.1.108 (4R)-2-(1-butyl-1H-indazol-3-yl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237839 3.5.1.108 (4R)-2-(2,4-dichlorophenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 32% inhibition 237840 3.5.1.108 (4R)-2-(2-butyl-2H-indazol-3-yl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237841 3.5.1.108 (4R)-2-(2H-1,3-benzodioxol-5-yl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 46% inhibition 237842 3.5.1.108 (4R)-2-(3,4-dichlorophenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 68% inhibition 237843 3.5.1.108 (4R)-2-(3,4-difluorophenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 60% inhibition 237844 3.5.1.108 (4R)-2-(3,4-dimethoxy-5-propylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide i.e L-161,240 26281 3.5.1.108 (4R)-2-(3,4-dimethoxy-5-propylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide the inhibitor is active against a Pseudomonas aeruginosa construct in which the endogenous lpxC gene is inactivated and in which LpxC activity is supplied by the lpxC gene from Escherichia coli. An Escherichia coli construct in which growth is dependent on the Pseudomonas aeruginosa lpxC gene is resistant to the compound 26281 3.5.1.108 (4R)-2-(3,4-dimethoxy-5-propylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 96% inhibition 26281 3.5.1.108 (4R)-2-(3,5-dichlorophenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 61% inhibition 237845 3.5.1.108 (4R)-2-(3,5-difluoro-4-methoxyphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 85% inhibition 237846 3.5.1.108 (4R)-2-(3,5-difluorophenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 37% inhibition 237847 3.5.1.108 (4R)-2-(3,5-dimethoxy-4-methylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 37% inhibition 237848 3.5.1.108 (4R)-2-(3,5-dimethoxyphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 67% inhibition 237849 3.5.1.108 (4R)-2-(3-bromo-4-fluorophenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 66% inhibition 237850 3.5.1.108 (4R)-2-(3-bromo-4-fluorophenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237850 3.5.1.108 (4R)-2-(3-bromo-5-fluoro-4-methoxyphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237851 3.5.1.108 (4R)-2-(3-chloro-4-fluorophenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 69% inhibition 237852 3.5.1.108 (4R)-2-(3-chloro-5-fluoro-1H-indol-2-yl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237853 3.5.1.108 (4R)-2-(3-cyanophenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 54% inhibition 237854 3.5.1.108 (4R)-2-(3-ethoxy-4-fluorophenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237855 3.5.1.108 (4R)-2-(3-fluoro-4-[[2-(trifluoromethyl)phenyl]methoxy]phenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237856 3.5.1.108 (4R)-2-(3-fluoro-4-[[3-(trifluoromethyl)phenyl]methoxy]phenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237857 3.5.1.108 (4R)-2-(4-acetylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237858 3.5.1.108 (4R)-2-(4-bromophenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237859 3.5.1.108 (4R)-2-(4-butylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 56% inhibition 237860 3.5.1.108 (4R)-2-(4-butylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237860 3.5.1.108 (4R)-2-(4-chloro-3-nitrophenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 70% inhibition 237861 3.5.1.108 (4R)-2-(4-ethoxy-3-oxobutyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 18% inhibition 237862 3.5.1.108 (4R)-2-(4-fluoro-3-methylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 59% inhibition 237863 3.5.1.108 (4R)-2-(4-fluoro-3-methylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237863 3.5.1.108 (4R)-2-(4-fluoro-3-nitrophenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 57% inhibition 237864 3.5.1.108 (4R)-2-(4-fluoro-3-propylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237865 3.5.1.108 (4R)-2-(4-fluorophenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237866 3.5.1.108 (4R)-2-(4-tert-butylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 58% inhibition 237867 3.5.1.108 (4R)-2-(5-fluoro-1H-indol-2-yl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237868 3.5.1.108 (4R)-2-(adamantan-1-yl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 71% inhibition 237869 3.5.1.108 (4R)-2-([1,1'-biphenyl]-4-yl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 69% inhibition 237870 3.5.1.108 (4R)-2-benzyl-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 34% inhibition 237871 3.5.1.108 (4R)-2-cyclopentyl-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 7% inhibition 237872 3.5.1.108 (4R)-2-dodecyl-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 60% inhibition 237873 3.5.1.108 (4R)-2-[(4-chlorophenyl)methyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 12% inhibition 237874 3.5.1.108 (4R)-2-[(E)-2-(2-chlorophenyl)ethenyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 36% inhibition 237875 3.5.1.108 (4R)-2-[(E)-2-(4-fluorophenyl)ethenyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 50% inhibition 237876 3.5.1.108 (4R)-2-[2-(ethylsulfanyl)pyridin-3-yl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 18% inhibition 237877 3.5.1.108 (4R)-2-[3,5-bis(trifluoromethyl)phenyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 57% inhibition 237878 3.5.1.108 (4R)-2-[3-(benzyloxy)-4-methoxyphenyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 8% inhibition 237879 3.5.1.108 (4R)-2-[3-chloro-4-(trifluoromethoxy)phenyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237880 3.5.1.108 (4R)-2-[3-fluoro-4-(trifluoromethyl)phenyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 55% inhibition 237881 3.5.1.108 (4R)-2-[3-fluoro-4-[(prop-2-en-1-yl)oxy]phenyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237882 3.5.1.108 (4R)-2-[3-fluoro-5-(trifluoromethyl)phenyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 12% inhibition 237883 3.5.1.108 (4R)-2-[4-(benzyloxy)-3,5-dimethylphenyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 61% inhibition 237884 3.5.1.108 (4R)-2-[4-(benzyloxy)-3-methoxyphenyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 13% inhibition 237885 3.5.1.108 (4R)-2-[4-(dimethylamino)phenyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237886 3.5.1.108 (4R)-2-[4-(hexyloxy)phenyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 86% inhibition 237887 3.5.1.108 (4R)-2-[4-fluoro-3-(trifluoromethyl)phenyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 77% inhibition 237888 3.5.1.108 (4R)-2-[4-[(3-fluorophenyl)methoxy]-3-(trifluoromethoxy)phenyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237889 3.5.1.108 (4R)-2-[4-[(but-3-en-1-yl)oxy]-3-(trifluoromethoxy)phenyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237890 3.5.1.108 (4R)-2-[4-[(but-3-en-1-yl)oxy]phenyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237891 3.5.1.108 (4R)-2-[4-[(but-3-en-1-yl)oxy]phenyl]-N-hydroxy-4,5-dihydro-1,3-thiazole-4-carboxamide - 237892 3.5.1.108 (4R)-2-[5-fluoro-4-methoxy-2-methyl-3-(prop-2-en-1-yl)phenyl]-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide - 237893 3.5.1.108 (4R)-N,4-dihydroxy-1-[4-(phenylethynyl)benzoyl]-L-prolinamide - 237894 3.5.1.108 (4R)-N,4-dihydroxy-1-[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)benzoyl]-L-prolinamide - 237895 3.5.1.108 (4R)-N,4-dihydroxy-1-[4-[(4-pentylphenyl)ethynyl]benzoyl]-L-prolinamide - 237896 3.5.1.108 (4R)-N,4-dihydroxy-1-[[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)phenyl]methyl]-L-prolinamide - 237897 3.5.1.108 (4R)-N-hydroxy-2-(1H-indazol-3-yl)-4,5-dihydro-1,3-oxazole-4-carboxamide - 237898 3.5.1.108 (4R)-N-hydroxy-2-(2,3,4-trifluorophenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 25% inhibition 237899 3.5.1.108 (4R)-N-hydroxy-2-(2,3,5-trifluoro-4-methoxyphenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 35% inhibition 237900 3.5.1.108 (4R)-N-hydroxy-2-(2-phenylcyclopropyl)-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 31% inhibition 237901 3.5.1.108 (4R)-N-hydroxy-2-(2-phenylethyl)-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 32% inhibition 237902 3.5.1.108 (4R)-N-hydroxy-2-(3,4,5-triethoxyphenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 86% inhibition 237903 3.5.1.108 (4R)-N-hydroxy-2-(3,4,5-trifluorophenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 54% inhibition 237904 3.5.1.108 (4R)-N-hydroxy-2-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 72% inhibition 237905 3.5.1.108 (4R)-N-hydroxy-2-(3-methoxyphenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 44% inhibition 237906 3.5.1.108 (4R)-N-hydroxy-2-(4'-propyl[1,1'-biphenyl]-4-yl)-4,5-dihydro-1,3-oxazole-4-carboxamide - 237907 3.5.1.108 (4R)-N-hydroxy-2-(4-iodophenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide - 237908 3.5.1.108 (4R)-N-hydroxy-2-(4-methoxy-3,5-dimethylphenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 71% inhibition 237909 3.5.1.108 (4R)-N-hydroxy-2-(4-methoxy-3-nitrophenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 78% inhibition 237910 3.5.1.108 (4R)-N-hydroxy-2-(4-methoxyphenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide i.e. L-159,692 38727 3.5.1.108 (4R)-N-hydroxy-2-(4-methoxyphenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 61% inhibition 38727 3.5.1.108 (4R)-N-hydroxy-2-(4-methyl-3-nitrophenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 79% inhibition 237911 3.5.1.108 (4R)-N-hydroxy-2-(4-methylphenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide - 237912 3.5.1.108 (4R)-N-hydroxy-2-(4-methylphenyl)-4,5-dihydro-1,3-thiazole-4-carboxamide - 237913 3.5.1.108 (4R)-N-hydroxy-2-(4-nitrophenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 57% inhibition 237914 3.5.1.108 (4R)-N-hydroxy-2-(4-nitrophenyl)-4,5-dihydro-1,3-oxazole-4-carboxamide - 237914 3.5.1.108 (4R)-N-hydroxy-2-(9-oxo-9H-fluoren-1-yl)-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 1% inhibition 237915 3.5.1.108 (4R)-N-hydroxy-2-(naphthalen-1-yl)-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 19% inhibition 237916 3.5.1.108 (4R)-N-hydroxy-2-(naphthalen-2-yl)-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 35% inhibition 237917 3.5.1.108 (4R)-N-hydroxy-2-(thiophen-2-yl)-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 19% inhibition 237918 3.5.1.108 (4R)-N-hydroxy-2-tricyclo[3.3.1.1-3,7]dec-1-yl-4,5-dihydro-1,3-oxazole-4-carboxamide 1 microg/ml, high inhibitory activity 150920 3.5.1.108 (4R)-N-hydroxy-2-[(1S,4R)-4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptan-1-yl]-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 8% inhibition 237919 3.5.1.108 (4R)-N-hydroxy-2-[(4-methoxyphenyl)methyl]-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 10% inhibition 237920 3.5.1.108 (4R)-N-hydroxy-2-[(E)-2-(4-methoxyphenyl)ethenyl]-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 48% inhibition 237921 3.5.1.108 (4R)-N-hydroxy-2-[(E)-2-(4-nitrophenyl)ethenyl]-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 1% inhibition 237922 3.5.1.108 (4R)-N-hydroxy-2-[(E)-2-phenylethenyl]-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 39% inhibition 237923 3.5.1.108 (4R)-N-hydroxy-2-[(E)-2-[3-(trifluoromethyl)phenyl]ethenyl]-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 32% inhibition 237924 3.5.1.108 (4R)-N-hydroxy-2-[(thiophen-2-yl)methyl]-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 17% inhibition 237925 3.5.1.108 (4R)-N-hydroxy-2-[3-(trifluoromethoxy)phenyl]-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 64% inhibition 237926 3.5.1.108 (4R)-N-hydroxy-2-[3-(trifluoromethyl)phenyl]-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 59% inhibition; 0.001 mg/ml, 65% inhibition 237927 3.5.1.108 (4R)-N-hydroxy-2-[4-(trifluoromethoxy)phenyl]-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 79% inhibition 237928 3.5.1.108 (4R)-N-hydroxy-2-[4-(trifluoromethyl)phenyl]-4,5-dihydro-1,3-oxazole-4-carboxamide - 237929 3.5.1.108 (4R)-N-hydroxy-2-[4-methoxy-3,5-bis(trifluoromethoxy)phenyl]-4,5-dihydro-1,3-thiazole-4-carboxamide - 237930 3.5.1.108 (4R)-N-hydroxy-2-[4-methoxy-3-(trifluoromethoxy)phenyl]-4,5-dihydro-1,3-oxazole-4-carboxamide - 237931 3.5.1.108 (4R)-N-hydroxy-2-[4-methoxy-3-propyl-5-(trifluoromethoxy)phenyl]-4,5-dihydro-1,3-oxazole-4-carboxamide - 237932 3.5.1.108 (4R)-N-hydroxy-2-[4-[(3-methylbut-2-en-1-yl)oxy]-3-(trifluoromethoxy)phenyl]-4,5-dihydro-1,3-oxazole-4-carboxamide - 237933 3.5.1.108 (4R)-N-hydroxy-2-[4-[(3-nitrophenoxy)methyl]phenyl]-4,5-dihydro-1,3-oxazole-4-carboxamide - 237934 3.5.1.108 (4R)-N-hydroxy-2-[4-[(3-nitrophenyl)methoxy]phenyl]-4,5-dihydro-1,3-oxazole-4-carboxamide - 237935 3.5.1.108 (4R)-N-hydroxy-2-[4-[(E)-phenyldiazenyl]phenyl]-4,5-dihydro-1,3-oxazole-4-carboxamide 0.001 mg/ml, 71% inhibition 237936 3.5.1.108 (4R)-N-hydroxy-2-[4-[(prop-2-en-1-yl)oxy]-3-(trifluoromethoxy)phenyl]-4,5-dihydro-1,3-oxazole-4-carboxamide - 237937 3.5.1.108 (4R)-N-hydroxy-2-[4-[(prop-2-en-1-yl)oxy]-3-(trifluoromethyl)phenyl]-4,5-dihydro-1,3-oxazole-4-carboxamide - 237938 3.5.1.108 (4R)-N-hydroxy-2-[6-(trifluoromethyl)pyridin-3-yl]-4,5-dihydro-1,3-oxazole-4-carboxamide - 237939 3.5.1.108 (4S)-1-(4-[[4-(dimethylamino)phenyl]ethynyl]benzoyl)-N,4-dihydroxy-L-prolinamide - 237948 3.5.1.108 (4S)-4-fluoro-N-hydroxy-1-[4-(phenylethynyl)benzoyl]-L-prolinamide - 237949 3.5.1.108 (4S)-N,4-dihydroxy-1-[4-([4-[(4-hydroxypiperidin-1-yl)methyl]phenyl]ethynyl)benzoyl]-L-prolinamide - 237950 3.5.1.108 (4S)-N,4-dihydroxy-1-[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)benzoyl]-L-prolinamide - 237951 3.5.1.108 (4S)-N,4-dihydroxy-1-[4-([4-[(piperidin-1-yl)methyl]phenyl]ethynyl)benzoyl]-L-prolinamide - 237952 3.5.1.108 (4S)-N,4-dihydroxy-1-[4-([4-[(thiomorpholin-4-yl)methyl]phenyl]ethynyl)benzoyl]-L-prolinamide - 237953 3.5.1.108 (R)-(hydroxyamino)((R)-2-(4-methoxy-3-propyl-5-(trifluoromethoxy)phenyl)-4,5-dihydrothiazol-4-yl)methanol - 74160 3.5.1.108 (R)-2-(1-butyl-1H-indazol-3-yl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 74157 3.5.1.108 (R)-2-(2-bromophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, nearly complete loss of activity 150897 3.5.1.108 (R)-2-(2-butyl-2H-indazol-3-yl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 74158 3.5.1.108 (R)-2-(3,4-dichlorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, exellent biological activity 150911 3.5.1.108 (R)-2-(3,4-difluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, exellent biological activity 150909 3.5.1.108 (R)-2-(3,4-dimethoxy-5-propylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml 74144 3.5.1.108 (R)-2-(3,5-dichlorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, moderate activity 150908 3.5.1.108 (R)-2-(3,5-difluoro-4-methoxyphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, good activity 74145 3.5.1.108 (R)-2-(3,5-difluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, moderate activity 74147 3.5.1.108 (R)-2-(3,5-dimethoxyphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, 67% inhibition 150891 3.5.1.108 (R)-2-(3-(dichloromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml 150904 3.5.1.108 (R)-2-(3-bromo-4-fluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, exellent biological activity 150912 3.5.1.108 (R)-2-(3-chloro-4-fluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, exellent biological activity 150910 3.5.1.108 (R)-2-(3-cyanophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml 150903 3.5.1.108 (R)-2-(3-ethoxy-4-fluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 74156 3.5.1.108 (R)-2-(3-fluoro-4-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, slight lower inhibitory activity than (R)-2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 150907 3.5.1.108 (R)-2-(3-fluoro-5-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, good activity 150913 3.5.1.108 (R)-2-(4-(3-fluorobenzyloxy)-3-(trifluoromethoxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 74153 3.5.1.108 (R)-2-(4-(allyloxy)-3-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 74151 3.5.1.108 (R)-2-(4-(dimethylamino)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 74154 3.5.1.108 (R)-2-(4-(hexyloxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, 86% inhibition 74146 3.5.1.108 (R)-2-(4-(hydroxycarbamoyl)-4,5-dihydrooxazol-2-yl)benzyl benzoate 1 microg/ml, nearly complete loss of activity 150896 3.5.1.108 (R)-2-(4-bromophenylsulfonamido)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxypropanamide - 74109 3.5.1.108 (R)-2-(4-chloro-3-nitrophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml 150901 3.5.1.108 (R)-2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 38778 3.5.1.108 (R)-2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, most potent compound 38778 3.5.1.108 (R)-2-(4-fluoro-3-methylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 74150 3.5.1.108 (R)-2-(4-fluoro-3-nitrophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml 150899 3.5.1.108 (R)-2-(4-tert-butylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, 58% inhibition 150894 3.5.1.108 (R)-2-(biphenyl-4-yl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, 69% inhibition 150893 3.5.1.108 (R)-2-decyl-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, high inhibitory activity 150919 3.5.1.108 (R)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxy-2-(naphthalene-2-sulfonamido)propanamide - 6330 3.5.1.108 (R)-4-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-2-isopropyl-4-oxobutanamide - 74132 3.5.1.108 (R)-4-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-2-methyl-4-oxobutanamide - 74140 3.5.1.108 (R)-N-(1-(2-(3,4-dimethoxy-5-propylphenyl)-4,5-dihydrooxazol-4-yl)vinyl)hydroxylamine - 74123 3.5.1.108 (R)-N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)-1H-indazole-3-carboxamide - 74152 3.5.1.108 (R)-N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)-4-methoxy-3-propyl-5-(trifluoromethoxy)benzamide - 74159 3.5.1.108 (R)-N-hydroxy-2-(1H-indazol-3-yl)-4,5-dihydrooxazole-4-carboxamide - 74155 3.5.1.108 (R)-N-hydroxy-2-(2,3,5-trifluoro-4-methoxyphenyl)-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, good activity 75591 3.5.1.108 (R)-N-hydroxy-2-(2-methylprop-1-enyl)-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, moderate activity 150914 3.5.1.108 (R)-N-hydroxy-2-(3,4,5-triethoxyphenyl)-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, 72% inhibition 150892 3.5.1.108 (R)-N-hydroxy-2-(3-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, exellent inhibitory activity 150906 3.5.1.108 (R)-N-hydroxy-2-(3-methoxyphenyl)-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, 44% inhibition 150890 3.5.1.108 (R)-N-hydroxy-2-(4-((3-nitrophenoxy)methyl)phenyl)-4,5-dihydrooxazole-4-carboxamide - 74149 3.5.1.108 (R)-N-hydroxy-2-(4-(3-nitrobenzyloxy)phenyl)-4,5-dihydrooxazole-4-carboxamide - 74162 3.5.1.108 (R)-N-hydroxy-2-(4-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide 1 microg/ml 150905 3.5.1.108 (R)-N-hydroxy-2-(4-hydroxyphenyl)-4,5-dihydrooxazole-4-carboxamide - 74163 3.5.1.108 (R)-N-hydroxy-2-(4-methoxy-3,5-dimethylphenyl)-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, 71% inhibition 150895 3.5.1.108 (R)-N-hydroxy-2-(4-methoxy-3-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide - 74161 3.5.1.108 (R)-N-hydroxy-2-(4-methoxy-3-nitrophenyl)-4,5-dihydrooxazole-4-carboxamide 1 microg/ml 150900 3.5.1.108 (R)-N-hydroxy-2-(4-methoxy-3-propyl-5-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide - 74148 3.5.1.108 (R)-N-hydroxy-2-(4-methoxyphenyl)-4,5-dihydrooxazole-4-carboxamide 1 microg/ml 150889 3.5.1.108 (R)-N-hydroxy-2-(4-methyl-3-nitrophenyl)-4,5-dihydrooxazole-4-carboxamide 1 microg/ml 150902 3.5.1.108 (R)-N-hydroxy-2-(4-nitrophenyl)-4,5-dihydrooxazole-4-carboxamide 1 microg/ml 150898 3.5.1.108 (R)-N-hydroxy-2-p-tolyl-4,5-dihydrothiazole-4-carboxamide - 74164 3.5.1.108 (R,E)-2-(2-chlorostyryl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, moderate activity 150918 3.5.1.108 (R,E)-N-hydroxy-2-(3-(trifluoromethyl)styryl)-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, moderate activity 150917 3.5.1.108 (R,E)-N-hydroxy-2-(4-nitrostyryl)-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, moderate activity 150916 3.5.1.108 (R,E)-N-hydroxy-2-styryl-4,5-dihydrooxazole-4-carboxamide 1 microg/ml, moderate activity 150915 3.5.1.108 (S)-3-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-4,5-dihydroisoxazole-5-carboxamide - 74136 3.5.1.108 (S)-3-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-5-methyl-4,5-dihydroisoxazole-5-carboxamide - 74133 3.5.1.108 (S)-3-(4-methoxyphenyl)-4,5-dihydro-isoxazole-5-carboxylic acid hydroxyamide - 74124 3.5.1.108 (S)-4-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-2-methyl-4-oxobutanamide - 74139 3.5.1.108 (S)-N-(1-(2-(3,4-dimethoxy-5-propylphenyl)-4,5-dihydrooxazol-4-yl)vinyl)hydroxylamine - 5846 3.5.1.108 (S)-N-(1-(2-(3,4-dimethoxy-5-propylphenyl)-4,5-dihydrooxazol-4-yl)vinyl)hydroxylamine phenyloxazoline hydroxamic acid, competitive inhibitor in Escherichia coli, not active as an antibiotic against Aquifex aeolicus, Pseudomonas aeruginosa and other clinically important pathogens 5846 3.5.1.108 (S)-N-hydroxy-1-(4-[[4-(morpholinomethyl)phenyl]ethynyl]benzyl)pyrrolidine-2-carboxamide highly active antibacterial compound 240111 3.5.1.108 1,5-anhydro-2,3-dideoxy-2-[2-(hydroxyamino)-2-oxoethyl]-D-ribo-hexitol - 238018 3.5.1.108 1,5-anhydro-2,4-dideoxy-2-[2-(hydroxyamino)-2-oxoethyl]-3-O-tetradecanoyl-D-xylo-hexitol 0.001 mg/ml, 18% inhibition 238019 3.5.1.108 1,5-anhydro-2,6-dideoxy-2-[2-(hydroxyamino)-2-oxoethyl]-3-O-tetradecanoyl-D-glucitol 0.001 mg/ml, 15% inhibition 238020 3.5.1.108 1,5-anhydro-2-C-(carboxymethyl-N-hydroxyamide)-2-deoxy-3-O-myristoyl-D-glucitol synthesis of the 13C-labeled substrate-analogue inhibitor, and the subsequent refinement of the solution structure of the LpxC-inhibitor complex using residual dipolar couplings. Structural basis for the design of more potent LpxC inhibitors. The best LpxC inhibitors should contain: (1) a zinc-chelating group situated between two hydrophobic molecular moieties and (2) a negatively charged group or polar group capable of forming salt bridges or hydrogen bonds with the basic patch. For the hydrophobic fragment to fit within the hydrophobic passage, a linear chemical group without branches is preferable and the total length from the hydroxamate group (which presumably binds Zn2+) to the terminal end of the linear fragment should be less than 15 A. Any hydrophobic group with a length beyond 15 A might require flexibility to fit the curved surface extending the hydrophobic passage, where the terminal methyl and the last two methylene groups of the 1,5-anhydro-2-C-(carboxymethyl-N-hydroxyamide)-2-deoxy-3-O-myristoyl-D-glucitol acyl chain are located 75589 3.5.1.108 1,5-anhydro-2-C-(carboxymethyl-N-hydroxyamide)-2-deoxy-3-O-myristoyl-D-glucitol the solution structure of LpxC in complex with the substrate-analog inhibitor 1,5-anhydro-2-C-(carboxymethyl-N-hydroxyamide)-2-deoxy-3-O-myristoyl-D-glucitol, reveals a novel alpha/beta fold, a unique zinc-binding motif and a hydrophobic passage that captures the acyl chain of the inhibitor 75589 3.5.1.108 1,5-anhydro-2-deoxy-2-[(2Z)-2-hydroxy-2-(hydroxyimino)ethyl]-3-O-tetradecanoyl-L-mannitol - 204761 3.5.1.108 1,5-anhydro-2-deoxy-2-[2-(hydroxyamino)-2-oxoethyl]-3-O-tetradecanoyl-D-glucitol the X-ray crystal structure of LpxC complexed with TU-514 allows for a detailed examination of the coordination geometry of the catalytic zinc ion and other enzyme-inhibitor interactions in the active site. The hydroxamate group of TU-514 forms a bidentate chelate complex with the zinc ion and makes hydrogen bond interactions with conserved active site residues E78, H265, and T191. The inhibitor C-4 hydroxyl group makes direct hydrogen bond interactions with E197 and H58. Finally, the C-3 myristate moiety of the inhibitor binds in the hydrophobic tunnel of the active site 151871 3.5.1.108 1,5-anhydro-2-deoxy-2-[2-(hydroxyamino)-2-oxoethyl]-3-O-tetradecanoyl-D-glucitol 0.001 mg/ml, 51% inhibition 151871 3.5.1.108 1,5-anhydro-2-deoxy-2-[2-(hydroxyamino)-2-oxoethyl]-3-O-tetradecyl-D-glucitol 0.001 mg/ml, 13% inhibition 238021 3.5.1.108 1,5-anhydro-2-deoxy-2-[2-(hydroxyamino)-2-oxoethyl]-3-O-[(3S)-3-hydroxyhexadecanoyl]-D-glucitol - 238022 3.5.1.108 1,5-anhydro-2-deoxy-2-[2-(hydroxyamino)-2-oxoethyl]-4-O-methyl-3-O-tetradecanoyl-D-glucitol 0.001 mg/ml, 30% inhibition 238023 3.5.1.108 1,5-anhydro-2-deoxy-2-[2-(hydroxyamino)-2-oxoethyl]-6-O-methyl-3-O-tetradecanoyl-D-glucitol 0.001 mg/ml, 3% inhibition 238024 3.5.1.108 1,5-anhydro-2-deoxy-3-O-hexadecanoyl-2-[2-(hydroxyamino)-2-oxoethyl]-D-glucitol 0.001 mg/ml, 11% inhibition 238025 3.5.1.108 1,5-anhydro-2-deoxy-3-O-hexanoyl-2-[2-(hydroxyamino)-2-oxoethyl]-D-glucitol - 238026 3.5.1.108 1,5-anhydro-2-deoxy-3-O-hexanoyl-2-[[hydroxy(methyl)phosphoryl]methyl]-D-glucitol - 238027 3.5.1.108 1,5-anhydro-3-O-benzoyl-2-deoxy-2-[2-(hydroxyamino)-2-oxoethyl]-D-glucitol 0.001 mg/ml, 53% inhibition 238028 3.5.1.108 1-benzyl-N-hydroxy-4-[4-(phenylethynyl)benzamido]piperidine-4-carboxamide - 238052 3.5.1.108 1-hydroxy-4-[4-[(3R)-4-(hydroxyamino)-3-(methanesulfonyl)-3-methyl-4-oxobutyl]phenoxy]pyridin-1-ium - 238054 3.5.1.108 1-[4-([4-[(1,1-dioxo-1lambda6-thiomorpholin-4-yl)methyl]phenyl]ethynyl)benzoyl]-N-hydroxy-L-prolinamide - 238076 3.5.1.108 2,3-dihydroxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime weak inhibitor 74167 3.5.1.108 2,4-dihydroxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime - 74166 3.5.1.108 2-(1-butyl-1H-indazol-3-yl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 14614 3.5.1.108 2-(2-butyl-2H-indazol-3-yl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 14615 3.5.1.108 2-(3,4-bis(trifluoromethoxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 75586 3.5.1.108 2-(3-(3-(cyclopentyloxy)-4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl)-N-hydroxyacetamide - 74134 3.5.1.108 2-(3-allyl-5-fluoro-4-methoxy-2-methylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 18909 3.5.1.108 2-(3-bromo-4-fluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 18910 3.5.1.108 2-(3-bromo-5-fluoro-4-methoxyphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 18908 3.5.1.108 2-(3-chloro-4-(trifluoromethoxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 18903 3.5.1.108 2-(3-chloro-5-fluoro-1H-indol-2-yl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 18916 3.5.1.108 2-(3-ethoxy-4-fluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 14610 3.5.1.108 2-(3-fluoro-4-(2-(trifluoromethyl)benzyloxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 74113 3.5.1.108 2-(3-fluoro-4-(3-(trifluoromethyl)benzyloxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 38768 3.5.1.108 2-(3-fluoro-4-(3-methylbenzyloxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 74131 3.5.1.108 2-(3-fluoro-5-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 18911 3.5.1.108 2-(4-(3-fluorobenzyloxy)-3-(trifluoromethoxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 18901 3.5.1.108 2-(4-(allyloxy)-3-(trifluoromethoxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 74110 3.5.1.108 2-(4-(allyloxy)-3-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 18912 3.5.1.108 2-(4-(allyloxy)-3-fluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 74112 3.5.1.108 2-(4-(but-3-enyloxy)-3-(trifluoromethoxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 18902 3.5.1.108 2-(4-(but-3-enyloxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 14606 3.5.1.108 2-(4-(but-3-enyloxy)phenyl)-N-hydroxy-4,5-dihydrothiazole-4-carboxamide - 14619 3.5.1.108 2-(4-(dimethylamino)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 14612 3.5.1.108 2-(4-(heptyloxy)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 38767 3.5.1.108 2-(4-acetamidophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 38769 3.5.1.108 2-(4-acetylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 18915 3.5.1.108 2-(4-bromophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 74115 3.5.1.108 2-(4-butylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 14605 3.5.1.108 2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 18906 3.5.1.108 2-(4-fluoro-3-(trifluoromethyl)phenyl)-N-hydroxy-5,6-dihydro-4H-1,3-oxazine-4-carboxamide - 74119 3.5.1.108 2-(4-fluoro-3-methylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 18907 3.5.1.108 2-(4-fluoro-3-propylphenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 14609 3.5.1.108 2-(4-fluorophenyl)-N-hydroxy-4,5-dihydro-1,3-thiazole-4-carboxamide - 238154 3.5.1.108 2-(4-fluorophenyl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 14608 3.5.1.108 2-(4-fluorophenyl)-N-hydroxy-4,5-dihydrothiazole-4-carboxamide - 74121 3.5.1.108 2-(5-fluoro-1H-indol-2-yl)-N-hydroxy-4,5-dihydrooxazole-4-carboxamide - 74117 3.5.1.108 2-(5-fluoro-1H-indol-2-yl)-N-hydroxy-5,6-dihydro-4H-1,3-oxazine-4-carboxamide - 74120 3.5.1.108 2-mercapto-1-[3-(4-methoxyphenyl)-4,5-dihydro-isoxazol-5-yl]ethanone racemate 74126 3.5.1.108 2-thioacetyl-1-[3-(4-methoxyphenyl)-4,5-dihydro-isoxazol-5-yl]ethanone racemate 74125 3.5.1.108 2-[([1,1'-biphenyl]-4-yl)methoxy]-N,3-dihydroxy-2-methylpropanamide - 238213 3.5.1.108 2-[4-fluoro-3-(trifluoromethyl)phenyl]-N-hydroxy-5,6-dihydro-4H-1,3-oxazine-4-carboxamide - 238227 3.5.1.108 2-[[([1,1'-biphenyl]-4-yl)oxy]methyl]-N,3-dihydroxy-2-methylpropanamide - 238233 3.5.1.108 2-[[4-(diethylamino)-2-hydroxyphenyl]carbonyl]benzoic acid compound shows good activity against Escherichia coli and Pseudomonas aeruginosa 28129 3.5.1.108 3,4,5-trihydroxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime weak inhibitor, contains a 5 position hydroxyl and exhibits greatly reduced inhibitory potency 74168 3.5.1.108 3,4-dihydroxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime 50 microM, 49% inhibition 74165 3.5.1.108 3-(3-(cyclopentyloxy)-4-methoxyphenyl)-4,5-dihydroisoxazole-5-carboxamide - 74138 3.5.1.108 3-(3-(cyclopentyloxy)-4-methoxyphenyl)-4,5-dihydroisoxazole-5-carboxylic acid - 74135 3.5.1.108 3-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-4,5-dihydroisoxazole-5-carboxamide - 75587 3.5.1.108 3-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-5-methyl-4,5-dihydroisoxazole-5-carboxamide - 75588 3.5.1.108 3-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-5-propyl-4,5-dihydroisoxazole-5-carboxamide - 74141 3.5.1.108 3-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-N-methyl-4,5-dihydroisoxazole-5-carboxamide - 74143 3.5.1.108 3-(4-methoxyphenyl)-4,5-dihydroisoxazol-5-yl(methyl)phosphinic acid - 74129 3.5.1.108 3-([1,1'-biphenyl]-4-sulfonyl)-N-hydroxy-2-(methanesulfonyl)-2-methylpropanamide - 238299 3.5.1.108 3-ethoxy-4-fluoro-N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)benzamide - 38774 3.5.1.108 3-ethoxy-4-fluoro-N-[(2R)-3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl]benzamide - 238328 3.5.1.108 3-[([1,1'-biphenyl]-4-yl)oxy]-N-hydroxy-2-(methanesulfonyl)-2-methylpropanamide - 238353 3.5.1.108 3-[([1,1'-biphenyl]-4-yl)sulfanyl]-N-hydroxy-2-(methanesulfonyl)-2-methylpropanamide - 238354 3.5.1.108 4'-ethyl-N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl][1,1'-biphenyl]-4-carboxamide - 238435 3.5.1.108 4'-[(3R)-4-(hydroxyamino)-3-(methanesulfonyl)-3-methyl-4-oxobutyl][1,1'-biphenyl]-3-carboxamide - 238437 3.5.1.108 4'-[(3R)-4-(hydroxyamino)-3-(methanesulfonyl)-3-methyl-4-oxobutyl][1,1'-biphenyl]-4-carboxylic acid - 238438 3.5.1.108 4-(3-(cyclopentyloxy)-4-methoxyphenyl)-4-oxobutanoic acid - 74142 3.5.1.108 4-(3-(cyclopentyloxy)-4-methoxyphenyl)-N-hydroxy-4-oxobutanamide - 74137 3.5.1.108 4-(4-[[4-(cyanomethyl)phenyl]ethynyl]phenyl)-N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]piperazine-1-carboxamide - 238447 3.5.1.108 4-(allyloxy)-N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)-3-(trifluoromethoxy)benzamide - 18917 3.5.1.108 4-(but-3-enyloxy)-N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)benzamide - 14616 3.5.1.108 4-([1,1'-biphenyl]-4-yl)-N-hydroxy-2-(hydroxymethyl)-2-methylbutanamide - 238457 3.5.1.108 4-([1,1'-biphenyl]-4-yl)-N-hydroxy-2-(methanesulfonyl)butanamide - 238458 3.5.1.108 4-([1,1'-biphenyl]-4-yl)-N-[(2S)-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]piperazine-1-carboxamide - 238459 3.5.1.108 4-([1,1'-biphenyl]-4-yl)-N-[(2S)-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]piperidine-1-carboxamide - 238460 3.5.1.108 4-([1,1'-biphenyl]-4-yl)-N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]piperazine-1-carboxamide - 238461 3.5.1.108 4-([1,1'-biphenyl]-4-yl)-N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]piperidine-1-carboxamide - 238462 3.5.1.108 4-([4'-[(3R)-4-(hydroxyamino)-3-(methanesulfonyl)-3-methyl-4-oxobutyl][1,1'-biphenyl]-4-yl]oxy)butanoic acid - 238463 3.5.1.108 4-([4-[(4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]phenyl)ethynyl]phenoxy]methyl)-N-hydroxyoxane-4-carboxamide - 238464 3.5.1.108 4-([[4-(4-chlorophenoxy)phenyl]sulfanyl]methyl)-N-hydroxyoxane-4-carboxamide - 238469 3.5.1.108 4-({4-[(2R,6S)-2,6-dimethylmorpholin-4-yl]phenoxy}methyl)-N-hydroxyoxane-4-carboxamide - 205149 3.5.1.108 4-({4-[(4-{[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl}phenyl)ethynyl]phenoxy}methyl)-N-hydroxyoxane-4-carboxamide - 205150 3.5.1.108 4-({[4-(4-chlorophenoxy)phenyl]sulfanyl}methyl)-N-hydroxyoxane-4-carboxamide - 205151 3.5.1.108 4-fluoro-N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)benzamide - 38773 3.5.1.108 4-[(4-[[4-([2-[(dimethylamino)methyl]morpholin-4-yl]methyl)phenyl]ethynyl]phenoxy)methyl]-N-hydroxyoxane-4-carboxamide - 238500 3.5.1.108 4-[(4-{2-[(dimethylamino)methyl]morpholin-4-yl}phenoxy)methyl]-N-hydroxyoxane-4-carboxamide - 205205 3.5.1.108 4-[(4-{[4-({2-[(dimethylamino)methyl]morpholin-4-yl}methyl)phenyl]ethynyl}phenoxy)methyl]-N-hydroxyoxane-4-carboxamide - 205206 3.5.1.108 4-[(but-3-en-1-yl)oxy]-N-[(2R)-3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl]benzamide - 238501 3.5.1.108 4-[4-[(4-aminophenyl)ethynyl]phenyl]-N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]piperazine-1-carboxamide - 238507 3.5.1.108 4-[4-[(4-chlorophenyl)ethynyl]phenyl]-N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]piperazine-1-carboxamide - 238508 3.5.1.108 4-[4-[(4-fluorophenyl)ethynyl]phenyl]-N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]piperazine-1-carboxamide - 238509 3.5.1.108 4-[[([1,1'-biphenyl]-4-yl)oxy]methyl]-N-hydroxyoxane-4-carboxamide - 238516 3.5.1.108 4-[[4-(benzyloxy)phenoxy]methyl]-N-hydroxyoxane-4-carboxamide - 238518 3.5.1.108 4-[[4-([4-[(4-acetylpiperazin-1-yl)methyl]phenyl]ethynyl)phenoxy]methyl]-N-hydroxyoxane-4-carboxamide - 238519 3.5.1.108 4-{[4-(4-acetylpiperazin-1-yl)phenoxy]methyl}-N-hydroxyoxane-4-carboxamide - 205227 3.5.1.108 4-{[4-({4-[(4-acetylpiperazin-1-yl)methyl]phenyl}ethynyl)phenoxy]methyl}-N-hydroxyoxane-4-carboxamide - 205228 3.5.1.108 5'-deoxy-5'-[2-([(E)-[(2,3,4-trihydroxyphenyl)methylidene]amino]oxy)acetamido]uridine - 238520 3.5.1.108 5'-O-[(E)-(2,3,4-trihydroxybenzylidene)amino]uridine 50 microM, 80% inhibition, pH-dependent, two-step, covalent inhibitor. 2,3,4-trihydroxybenzaldehyde O-((2R,3R,4S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime represents a new class of LpxC inhibitors that exploit the uridine binding site to form a covalent complex. While not antibiotic, it may provide a new scaffold for extension of existing LpxC-inhibiting antibiotics to target the UDP binding pocket 26697 3.5.1.108 5'-O-[(E)-(2,3,4-trihydroxybenzylidene)amino]uridine 50 microM, 21% inhibition, pH-dependent, two-step, covalent inhibitor. 2,3,4-trihydroxybenzaldehyde O-((2R,3R,4S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime represents a new class of LpxC inhibitors that exploit the uridine binding site to form a covalent complex. While not antibiotic, it may provide a new scaffold for extension of existing LpxC-inhibiting antibiotics to target the UDP binding pocket 26697 3.5.1.108 5'-O-[(E)-(3,4-dihydroxybenzylidene)amino]uridine 50 microM, 60% inhibition, inhibitor as potent as (E)-2,3,4-trihydroxybenzaldehyde O-((2R,3R,4S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime 75590 3.5.1.108 5'-O-[(E)-(3,4-dihydroxybenzylidene)amino]uridine 50 microM, 41% inhibition 75590 3.5.1.108 5'-O-[(E)-[(2,3,4-trihydroxyphenyl)methylidene]amino]uridine - 238521 3.5.1.108 5'-O-[(E)-[(3,4-dihydroxyphenyl)methylidene]amino]uridine - 238522 3.5.1.108 5-ethyl-5-(2-oxo-2-[4-[4-(phenylethynyl)phenyl]piperidin-1-yl]ethyl)imidazolidine-2,4-dione - 238556 3.5.1.108 5-methyl-5-(2-oxo-2-[4-[4-(phenylethynyl)phenyl]piperazin-1-yl]ethyl)imidazolidine-2,4-dione - 238557 3.5.1.108 5-methyl-5-(2-oxo-2-[4-[4-(phenylethynyl)phenyl]piperidin-1-yl]ethyl)imidazolidine-2,4-dione - 238558 3.5.1.108 6-(1H-benzimidazol-1-yl)-N-hydroxy-5-[4-([6-[(4-methylpiperazin-1-yl)methyl]pyridin-3-yl]ethynyl)phenyl]pyridine-3-carboxamide crystal structure of inhibitor B bound to the enzyme 205347 3.5.1.108 Ciprofloxacin - 1229 3.5.1.108 dipicolinic acid 0.02 mM, complete inhibition 1443 3.5.1.108 EDTA 5 mM, complete loss of activity 21 3.5.1.108 EDTA t1/2: 4 min at 0.005 mM EDTA at 1 °C 21 3.5.1.108 EDTA 0.002 mM, complete inactivation, reactivated by the addition of excess heavy metal 21 3.5.1.108 meropenem - 917 3.5.1.108 additional information (R)-2-(4-bromophenylsulfonamido)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxypropanamide and (R)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxy-2-(naphthalene-2-sulfonamido)propanamide show predominantly gram-negative activities, with activities against members of the Enterobacteriaceae, Serratia marcescens, Morganella morganii, Moraxella catarrhalis, Haemophilus influenzae, and Burkholderia cepacia. Neither compound showed activity against Pseudomonas aeruginosa; however, against a leaky Pseudomonas aeruginosa strain, some activity is seen with (R)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxy-2-(naphthalene-2-sulfonamido)propanamide. (R)-2-(4-bromophenylsulfonamido)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxypropanamide and (R)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxy-2-(naphthalene-2-sulfonamido)propanamide have little or no activity against the gram-positive bacteria tested 2 3.5.1.108 additional information (4R)-2-(3,4-dimethoxy-5-propylphenyl)-N-hydroxy-4,5-dihydro-1,3-oxazole-4-carboxamide is active against a Pseudomonas aeruginosa construct in which the endogenous lpxC gene is inactivated and in which LpxC activity is supplied by the lpxC gene from Escherichia coli. An Escherichia coli construct in which growth is dependent on the Pseudomonas aeruginosa lpxC gene is resistant to the compound 2 3.5.1.108 additional information incubation of 10 nM LpxC in buffer without bovine serum albumin for 30 min completely inactivates the enzyme. When this enzyme is diluted further (4fold) into buffer containing 1 mg/ml bovine serum albumin, 100% of the activity is restored when assayed after a 2 h incubation. High concentrations of LpxC in the assays can eliminate the requirement of bovine serum albumin 2 3.5.1.108 additional information (S)-N-(1-(2-(3,4-dimethoxy-5-propylphenyl)-4,5-dihydrooxazol-4-yl)vinyl)hydroxylamine, phenyloxazoline hydroxamic acid, competitive inhibitor in Escherichia coli, not active as an antibiotic against Aquifex aeolicus, Pseudomonas aeruginosa and other clinically important pathogens 2 3.5.1.108 additional information the affinity of LpxC for both product and fatty acids is significantly influenced by changes in the number and identity of metal ions bound to the LpxC active site. Therefore, interactions with these metal ions are critical for molecular recognition of ligands by LpxC and may mimic similar contacts with active site inhibitors. These data indicate that the potency of LpxC inhibitors in vitro can be altered by assay conditions used in screening and/or development of LpxC inhibitors and that the metal ion status of LpxC in vivo will likely influence the effectiveness of LpxC inhibitors as antibiotics 2 3.5.1.108 additional information dithiothreitol, glutathione and the C207A mutant prevent the formation of a covalent complex by (E)-2,3,4-trihydroxybenzaldehyde O-((2R,3R,4S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl oxime; no inhibitory effect by 2,4-dihydroxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime, 3,4-dimethoxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime, and 2,3,4-trimethoxy-benzaldehyde O-[5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-3,4-dihydroxy-tetrahydro-furan-2-ylmethyl]-oxime 2 3.5.1.108 additional information mass spectrometry-based screening is a valuable high-throughput screening tool for detecting inhibitors of enzymatic targets involving difficult to detect reactions 2 3.5.1.108 additional information study the potentially important structural differences in active sites of both proteins responsible for making the inhibitors selective for Escherichia coli as compared to Pseudomonas aeruginosa LpxC, homology models of the LpxC of both organisms are developed and validated on the basis of a 3D profile and PROCHECK. Subsequently, a molecular electrostatic potential (MEP)-based surface and cavity-depth analysis is performed. Finally, a cross-docking analysis of reported inhibitors is performed to reveal selective binding modes. These studies identify differences between the two active sites and have implications for designing effective strategies to identify LpxC inhibitors that can be developed as novel broad-spectrum antibacterial drugs 2 3.5.1.108 additional information (S)-N-(1-(2-(3,4-dimethoxy-5-propylphenyl)-4,5-dihydrooxazol-4-yl)vinyl)hydroxylamine and (R)-3-(5,8-dihydronaphthalen-2-yl)-N-hydroxy-2-(naphthalene-2-sulfonamido)propanamide do not inhibit Aquifex aeolicus LpxC 2 3.5.1.108 additional information no evidence of time-dependent inhibition is observed in assays with either the wild-type or mutants 2 3.5.1.108 additional information synthesis, structure, structure-activity relationship, and inhibitory potencies of tetrahydropyran-based LpxC inhibitors, overview 2 3.5.1.108 additional information structure-guided drug discovery of broad spectrum Gram-negative antibiotics, overview 2 3.5.1.108 additional information evaluation of LpxC inhibitors that are potent and rapidly bactericidal against multiple Gram-negative species, overview 2 3.5.1.108 additional information structure-based drug design, inhibitor binding structures, overview 2 3.5.1.108 additional information development of novel LpxC inhibitors, chiral-pool synthesis of C-triazolyl glycosides, biological activity against Escherichia coli strains BL21(DE3) and D22, overview 2 3.5.1.108 additional information C-triazolyl beta-D-furanosides as LpxC inhibitors, stereoselective synthesis and evaluation, biological activity against Escherichia coli strains BL21(DE3) and D22, overview 2 3.5.1.108 additional information synthesis and biological evaluation of C-ethynyl furanosides as enzyme LpxC inhibitors, biological activity against Escherichia coli strains BL21(DE3) and D22, overview 2 3.5.1.108 N'-formyl-3-(4-methoxyphenyl)-4,5-dihydroisoxazole-5-carbohydrazide - 74127 3.5.1.108 N,4-dihydroxy-1-{[4-({4-[(morpholin-4-yl)methyl]phenyl}ethynyl)phenoxy]methyl}cyclohexane-1-carboxamide - 205478 3.5.1.108 N-(((2R,3R,4S,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)-2-((Z)-2,3,4-trihydroxybenzylideneaminooxy)acetamide - 74169 3.5.1.108 N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide N-aroyl-L-threonine hydroxamic acid, antibiotic activity comparable to ciprofloxacin, slow, tight-binding LpxC inhibitor 5847 3.5.1.108 N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide - 5847 3.5.1.108 N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide as effectively as ciprofloxacin or tobramycin 5847 3.5.1.108 N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide wild-type is insensitive to N-((2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl)-4-((4-(morpholinomethyl)phenyl)ethynyl)benzamide 5847 3.5.1.108 N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)-1H-indazole-3-carboxamide - 14617 3.5.1.108 N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)-4-(trifluoromethoxy)benzamide - 38775 3.5.1.108 N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)-4-methoxy-3-propyl-5-(trifluoromethoxy)benzamide - 38776 3.5.1.108 N-(3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl)-4-methylbenzamide - 38772 3.5.1.108 N-ethylmaleimide 1 mM, complete inhibition 49 3.5.1.108 N-hydroxy-1,1-dioxo-4-[4-(phenylethynyl)benzamido]-1lambda6-thiane-4-carboxamide - 240112 3.5.1.108 N-hydroxy-1-[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)benzoyl]-D-prolinamide - 238823 3.5.1.108 N-hydroxy-1-[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)benzoyl]-L-prolinamide - 238824 3.5.1.108 N-hydroxy-1-[4-([4-[(thiomorpholin-4-yl)methyl]phenyl]ethynyl)benzoyl]-L-prolinamide - 238825 3.5.1.108 N-hydroxy-1-[[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)phenyl]methyl]-L-prolinamide - 238826 3.5.1.108 N-hydroxy-1-[[4-([4-[(thiomorpholin-4-yl)methyl]phenyl]ethynyl)phenyl]methyl]-L-prolinamide - 238827 3.5.1.108 N-hydroxy-2-(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)-4,5-dihydrooxazole-4-carboxamide - 38771 3.5.1.108 N-hydroxy-2-(1H-indazol-3-yl)-4,5-dihydrooxazole-4-carboxamide - 14613 3.5.1.108 N-hydroxy-2-(2-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide - 38766 3.5.1.108 N-hydroxy-2-(3-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide - 14603 3.5.1.108 N-hydroxy-2-(3-(trifluoromethyl)phenyl)-4,5-dihydrooxazole-4-carboxamide - 14611 3.5.1.108 N-hydroxy-2-(3-propyl-4,5-bis(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide - 39098 3.5.1.108 N-hydroxy-2-(4'-propylbiphenyl-4-yl)-4,5-dihydrooxazole-4-carboxamide - 14607 3.5.1.108 N-hydroxy-2-(4-((3-nitrophenoxy)methyl)phenyl)-4,5-dihydrooxazole-4-carboxamide - 18905 3.5.1.108 N-hydroxy-2-(4-(3-methylbut-2-enyloxy)-3-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide - 74111 3.5.1.108 N-hydroxy-2-(4-(3-nitrobenzyloxy)phenyl)-4,5-dihydrooxazole-4-carboxamide - 18904 3.5.1.108 N-hydroxy-2-(4-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide - 14604 3.5.1.108 N-hydroxy-2-(4-(trifluoromethoxy)phenyl)-4,5-dihydrothiazole-4-carboxamide - 74122 3.5.1.108 N-hydroxy-2-(4-(trifluoromethyl)phenyl)-4,5-dihydrooxazole-4-carboxamide - 18913 3.5.1.108 N-hydroxy-2-(4-hydroxyphenyl)-4,5-dihydrooxazole-4-carboxamide - 26329 3.5.1.108 N-hydroxy-2-(4-iodophenyl)-4,5-dihydrooxazole-4-carboxamide - 74116 3.5.1.108 N-hydroxy-2-(4-methoxy-3-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide - 38765 3.5.1.108 N-hydroxy-2-(4-methoxy-3-propyl-5-(trifluoromethoxy)phenyl)-4,5-dihydrooxazole-4-carboxamide - 38764 3.5.1.108 N-hydroxy-2-(4-methoxy-3-propyl-5-(trifluoromethoxy)phenyl)-4,5-dihydrothiazole-4-carboxamide - 26330 3.5.1.108 N-hydroxy-2-(4-nitrophenyl)-4,5-dihydrooxazole-4-carboxamide - 74114 3.5.1.108 N-hydroxy-2-(5-methyl-1-phenyl-1H-pyrazol-4-yl)-4,5-dihydrooxazole-4-carboxamide - 38770 3.5.1.108 N-hydroxy-2-(5-methyl-1-phenyl-1H-pyrazol-4-yl)-4,5-dihydrothiazole-4-carboxamide - 38777 3.5.1.108 N-hydroxy-2-(6-(trifluoromethyl)pyridin-3-yl)-4,5-dihydrooxazole-4-carboxamide - 18914 3.5.1.108 N-hydroxy-2-p-tolyl-4,5-dihydrooxazole-4-carboxamide - 14602 3.5.1.108 N-hydroxy-2-p-tolyl-4,5-dihydrothiazole-4-carboxamide - 14618 3.5.1.108 N-hydroxy-2-p-tolyl-5,6-dihydro-4H-1,3-oxazine-4-carboxamide - 74118 3.5.1.108 N-hydroxy-2-[(1R)-2-hydroxy-1-[4-(phenylethynyl)phenyl]ethoxy]acetamide - 238832 3.5.1.108 N-hydroxy-2-[(1R)-2-hydroxy-1-[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)phenyl]ethoxy]acetamide - 238833 3.5.1.108 N-hydroxy-2-[(1S)-2-hydroxy-1-[4-(phenylethynyl)phenyl]ethoxy]acetamide - 238834 3.5.1.108 N-hydroxy-2-[(1S)-2-hydroxy-1-[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)phenyl]ethoxy]acetamide - 238835 3.5.1.108 N-hydroxy-2-[4-(trifluoromethoxy)phenyl]-4,5-dihydro-1,3-thiazole-4-carboxamide - 238836 3.5.1.108 N-hydroxy-2-[[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)phenyl]methoxy]acetamide - 238837 3.5.1.108 N-hydroxy-4-([4-[(4-[[4-(propan-2-yl)piperazin-1-yl]methyl]phenyl)ethynyl]phenoxy]methyl)oxane-4-carboxamide - 238846 3.5.1.108 N-hydroxy-4-([[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)phenyl]sulfanyl]methyl)oxane-4-carboxamide - 238847 3.5.1.108 N-hydroxy-4-({4-[(4-{[4-(propan-2-yl)piperazin-1-yl]methyl}phenyl)ethynyl]phenoxy}methyl)oxane-4-carboxamide - 205590 3.5.1.108 N-hydroxy-4-({4-[4-(propan-2-yl)piperazin-1-yl]phenoxy}methyl)oxane-4-carboxamide - 205591 3.5.1.108 N-hydroxy-4-({[4-({4-[(morpholin-4-yl)methyl]phenyl}ethynyl)phenyl]sulfanyl}methyl)oxane-4-carboxamide - 205592 3.5.1.108 N-hydroxy-4-methoxy-1-[[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)phenoxy]methyl]cyclohexane-1-carboxamide - 238848 3.5.1.108 N-hydroxy-4-methoxy-1-{[4-({4-[(morpholin-4-yl)methyl]phenyl}ethynyl)phenoxy]methyl}cyclohexane-1-carboxamide - 205593 3.5.1.108 N-hydroxy-4-[(4-phenoxyphenoxy)methyl]oxane-4-carboxamide - 238849 3.5.1.108 N-hydroxy-4-[(4-[[4-([4-[2-(1H-imidazol-1-yl)ethyl]piperazin-1-yl]methyl)phenyl]ethynyl]phenoxy)methyl]oxane-4-carboxamide - 238850 3.5.1.108 N-hydroxy-4-[(4-[[4-([4-[2-(morpholin-4-yl)-2-oxoethyl]piperazin-1-yl]methyl)phenyl]ethynyl]phenoxy)methyl]oxane-4-carboxamide - 238851 3.5.1.108 N-hydroxy-4-[(4-[[4-([4-[2-(morpholin-4-yl)ethyl]piperazin-1-yl]methyl)phenyl]ethynyl]phenoxy)methyl]oxane-4-carboxamide - 238852 3.5.1.108 N-hydroxy-4-[(4-[[4-([[(4-methoxyphenyl)methyl]amino]methyl)phenyl]ethynyl]phenoxy)methyl]oxane-4-carboxamide - 238853 3.5.1.108 N-hydroxy-4-[(4-{4-[2-(morpholin-4-yl)ethyl]piperazin-1-yl}phenoxy)methyl]oxane-4-carboxamide - 205594 3.5.1.108 N-hydroxy-4-[(4-{[4-({4-[2-(1H-imidazol-1-yl)ethyl]piperazin-1-yl}methyl)phenyl]ethynyl}phenoxy)methyl]oxane-4-carboxamide - 205595 3.5.1.108 N-hydroxy-4-[(4-{[4-({4-[2-(morpholin-4-yl)-2-oxoethyl]piperazin-1-yl}methyl)phenyl]ethynyl}phenoxy)methyl]oxane-4-carboxamide - 205596 3.5.1.108 N-hydroxy-4-[(4-{[4-({4-[2-(morpholin-4-yl)ethyl]piperazin-1-yl}methyl)phenyl]ethynyl}phenoxy)methyl]oxane-4-carboxamide - 205597 3.5.1.108 N-hydroxy-4-[(4-{[4-({[(4-methoxyphenyl)methyl]amino}methyl)phenyl]ethynyl}phenoxy)methyl]oxane-4-carboxamide - 205598 3.5.1.108 N-hydroxy-4-[4-(phenylethynyl)benzamido]oxane-4-carboxamide - 238854 3.5.1.108 N-hydroxy-4-[4-(phenylethynyl)benzamido]piperidine-4-carboxamide - 238855 3.5.1.108 N-hydroxy-4-[4-(phenylethynyl)benzamido]thiane-4-carboxamide - 238856 3.5.1.108 N-hydroxy-4-[[4-(4-phenylbuta-1,3-diyn-1-yl)phenoxy]methyl]oxane-4-carboxamide - 238857 3.5.1.108 N-hydroxy-4-[[4-(5-hydroxy-5-methylhexa-1,3-diyn-1-yl)phenoxy]methyl]oxane-4-carboxamide - 238858 3.5.1.108 N-hydroxy-4-[[4-([4-[(4-methylpiperazin-1-yl)methyl]phenyl]ethynyl)phenoxy]methyl]oxane-4-carboxamide - 238859 3.5.1.108 N-hydroxy-4-[[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)benzene-1-sulfinyl]methyl]oxane-4-carboxamide - 238860 3.5.1.108 N-hydroxy-4-[[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)phenoxy]methyl]oxane-4-carboxamide - 238861 3.5.1.108 N-hydroxy-4-{[4-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}ethynyl)phenoxy]methyl}oxane-4-carboxamide - 205601 3.5.1.108 N-hydroxy-4-{[4-({4-[(morpholin-4-yl)methyl]phenyl}ethynyl)benzene-1-sulfinyl]methyl}oxane-4-carboxamide - 205602 3.5.1.108 N-hydroxy-4-{[4-({4-[(morpholin-4-yl)methyl]phenyl}ethynyl)phenoxy]methyl}oxane-4-carboxamide - 205603 3.5.1.108 N-hydroxy-6-(1H-imidazol-1-yl)-5-[4-([6-[(4-methylpiperazin-1-yl)methyl]pyridin-3-yl]ethynyl)phenyl]pyridine-3-carboxamide - 205606 3.5.1.108 N-hydroxy-N2-([2-[4-(phenylethynyl)phenyl]ethyl]carbamoyl)-L-threoninamide - 238862 3.5.1.108 N-hydroxy-N2-([[4-(phenylethynyl)phenyl]methyl]carbamoyl)-L-threoninamide - 238863 3.5.1.108 N-hydroxy-Nalpha-[4-(phenylethynyl)benzoyl]-L-histidinamide - 238873 3.5.1.108 N-[(1R)-2-(hydroxyamino)-2-oxo-1-phenylethyl]-4-(phenylethynyl)benzamide - 238879 3.5.1.108 N-[(1S)-2-(hydroxyamino)-2-oxo-1-phenylethyl]-4-(phenylethynyl)benzamide - 238883 3.5.1.108 N-[(2R)-1-(hydroxyamino)-3-(methanesulfonyl)-1-oxopropan-2-yl]-4-(phenylethynyl)benzamide - 238891 3.5.1.108 N-[(2R)-1-(hydroxyamino)-3-(methylsulfanyl)-1-oxopropan-2-yl]-4-(phenylethynyl)benzamide - 238892 3.5.1.108 N-[(2R)-3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl]-1H-indazole-3-carboxamide - 238894 3.5.1.108 N-[(2R)-3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl]-4-(phenylethynyl)benzamide - 238895 3.5.1.108 N-[(2R)-3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl]-4-(trifluoromethoxy)benzamide - 238896 3.5.1.108 N-[(2R)-3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl]-4-[(prop-2-en-1-yl)oxy]-3-(trifluoromethoxy)benzamide - 238897 3.5.1.108 N-[(2S)-3-amino-1-(hydroxyamino)-1-oxopropan-2-yl]-4-(phenylethynyl)benzamide - 238910 3.5.1.108 N-[(2S)-3-amino-1-(hydroxyamino)-1-oxopropan-2-yl]-4-[4-(phenylethynyl)phenyl]piperidine-1-carboxamide - 238911 3.5.1.108 N-[(2S)-3-hydroxy-1-(hydroxyamino)-1-oxopropan-2-yl]-4-(phenylethynyl)benzamide - 238912 3.5.1.108 N-[(2S)-3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-4-[4-(phenylethynyl)phenyl]piperazine-1-carboxamide - 238913 3.5.1.108 N-[(2S,3R)-3-amino-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4-(phenylethynyl)phenyl]piperazine-1-carboxamide - 238931 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-3-[3-(phenylethynyl)phenyl]pyrrolidine-1-carboxamide - 238932 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-3-[4-(phenylethynyl)phenyl]piperidine-1-carboxamide - 238933 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-3-[4-(phenylethynyl)phenyl]pyrrolidine-1-carboxamide - 238934 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-((4-[(morpholin-4-yl)methyl]phenyl)ethynyl)benzamide - 206431 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-(4-phenylbuta-1,3-diyn-1-yl)benzamide - 205690 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-(4-[[4-(hydroxymethyl)phenyl]ethynyl]phenyl)piperazine-1-carboxamide - 238935 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-(4-[[4-(morpholin-4-yl)phenyl]ethynyl]phenyl)piperazine-1-carboxamide - 238936 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-(4-[[4-(piperazin-1-yl)phenyl]ethynyl]phenyl)piperazine-1-carboxamide - 238937 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-(4-[[4-(trifluoromethyl)phenyl]ethynyl]phenyl)piperazine-1-carboxamide - 238938 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-(phenylethynyl)benzamide - 238939 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-(phenylethynyl)piperidine-1-carboxamide - 238940 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)benzamide - 238941 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-([6-[(morpholin-4-yl)methyl]pyridin-3-yl]ethynyl)benzamide - 205691 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-({4-[(morpholin-4-yl)methyl]phenyl}ethynyl)benzamide - 205692 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-phenylpiperidine-1-carboxamide - 238942 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4'-(morpholin-4-yl)[1,1'-biphenyl]-4-yl]piperazine-1-carboxamide - 238943 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4-(1,3-thiazol-5-yl)phenyl]piperazine-1-carboxamide - 238944 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4-(phenylethynyl)phenyl]piperazine-1-carboxamide - 238945 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4-(phenylethynyl)phenyl]piperidine-1-carboxamide - 238946 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4-([4-[(morpholin-4-yl)methyl]phenyl]ethynyl)phenyl]piperazine-1-carboxamide - 238947 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4-[(4-hydroxyphenyl)ethynyl]phenyl]piperazine-1-carboxamide - 238948 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4-[(pyrazin-2-yl)ethynyl]phenyl]piperazine-1-carboxamide - 238949 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4-[(pyridin-2-yl)ethynyl]phenyl]piperazine-1-carboxamide - 238950 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4-[(pyridin-3-yl)ethynyl]phenyl]piperazine-1-carboxamide - 238951 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4-[(pyridin-4-yl)ethynyl]phenyl]piperazine-1-carboxamide - 238952 3.5.1.108 N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4-[(thiophen-2-yl)ethynyl]phenyl]piperazine-1-carboxamide - 238953 3.5.1.108 N-[1-(hydroxyamino)-1-oxopropan-2-yl]-4-(phenylethynyl)benzamide - 238994 3.5.1.108 N-[1-(hydroxyamino)-2-methyl-1-oxopropan-2-yl]-4-(phenylethynyl)benzamide - 238995 3.5.1.108 N-[1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-4-(phenylethynyl)benzamide - 238996 3.5.1.108 N-[1-(hydroxycarbamoyl)cyclobutyl]-4-(phenylethynyl)benzamide - 238997 3.5.1.108 N-[1-(hydroxycarbamoyl)cyclohexyl]-4-(phenylethynyl)benzamide - 238998 3.5.1.108 N-[2-(hydroxyamino)-2-oxoethyl]-4-(phenylethynyl)benzamide - 239010 3.5.1.108 N-[3-amino-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4-(phenylethynyl)phenyl]piperazine-1-carboxamide compound shows good activity against Escherichia coli and Pseudomonas aeruginosa 86985 3.5.1.108 N-[3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-(phenylethynyl)benzamide compound shows good activity against Escherichia coli and Pseudomonas aeruginosa 86982 3.5.1.108 N-[3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[4-(phenylethynyl)phenyl]piperidine-1-carboxamide compound shows good activity against Escherichia coli and Pseudomonas aeruginosa 86983 3.5.1.108 N-[3-hydroxy-1-(hydroxyamino)-2-methyl-1-oxopropan-2-yl][1,1'-biphenyl]-4-carboxamide - 239022 3.5.1.108 N-[3-hydroxy-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl]-4-[4-(phenylethynyl)phenyl]piperazine-1-carboxamide compound shows good activity against Escherichia coli and Pseudomonas aeruginosa 86984 3.5.1.108 N1-hydroxy-N2-[4-(phenylethynyl)benzoyl]-N4-prop-2-yn-1-yl-L-aspartamide - 239038 3.5.1.108 N1-hydroxy-N4-(2-methoxyethyl)-N2-[4-(phenylethynyl)benzoyl]-L-aspartamide - 239039 3.5.1.108 N1-hydroxy-N4-(3-hydroxypropyl)-N2-[4-(phenylethynyl)benzoyl]-L-aspartamide - 239040 3.5.1.108 RS-130830 - 206430 3.5.1.108 tobramycin - 939 3.5.1.108 Zn2+ 0.1 mM, about 65% loss of activity 14 3.5.1.108 Zn2+ - 14 3.5.1.108 [2-[(4R)-4-(hydroxycarbamoyl)-4,5-dihydro-1,3-oxazol-2-yl]phenyl]methyl benzoate 0.001 mg/ml, 35% inhibition 239148 3.5.1.108 [3-(4-methoxyphenyl)-4,5-dihydro-isoxazol-5-yl]phosphonic acid - 74128